Sanofi (NASDAQ: SNY) reported Q1 EPS of EUR1.79, EUR0.12 better than the analyst estimate of EUR1.67. Revenue for the quarter came in at EUR9.89 billion versus the consensus estimate of EUR10.99 billion.

Guidance confirmed
• In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5. Sanofi confirms the expectation of a
strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6
• Sanofi intends to complete a share buyback program in 2025 of €5 billion of which 72% was already repurchased

For earnings history and earnings-related data on Sanofi (SNY) click here.